Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review

Document Type: Review Paper

Authors

1 4. Resident of Clinical Pharmacy, Department of Clinical Pharmacy, faculty of Pharmacy, University of Medical Sciences, Mazandaran, Sari, Iran

2 Associate Professor of Clinical Pharmacy, Department of Clinical Pharmacy, faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

3 Assistant professor of cardiology, Mazandaran University of medical Sciences, Sari, Iran

4 Assistant Professor, Mazandaran University of Medical Sciences, Sari, Iran

5 1. Associate Professor of Clinical Pharmacy, Department of Clinical Pharmacy, faculty of Pharmacy, Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

abstract:
Acute Venous Thromboembolism (VTE) is a common disease associated with the significant morbidity and mortality. We reviewed clinical outcomes systematically with Dabigatran as a direct oral anticoagulants (DOAC) for treatment of acute VTE. We used Ovide, PubMed, Cochrane (CENTRAL), EMBASE, Scopus, Science Direct, LILAC(for article written not English) and also Iranian database; Magiran, Isc, Iran Medex, Iran DOC, Doaj up to May 2014 to identify randomized clinical trials of Dabigatran compared with conventional treatment for VTE. Two investigators extracted data independently.
Number of 5107 patients including two trails were selected. The risk of recurrent VTE was similar with the Dabigatran and standard treatment (Hazard Ratio, 95% confidence interval 1.09 (0.76–1.57). Dabigatran reduced the risk of minor bleeding in comparison with standard treatment; Warfarin (0.62 (0.50–0.76).
Finally- in minor bleeding - the Dabigatran seemed as effective as, and probably safer than standard treatment of acute VTE. But in some aspects such as adherence to treatment, pregnant patient, impact on quality of life, new researches are needed to be clarified.

Keywords

Main Subjects